Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations

Journal of Clinical Oncology

Volumn 29, Issue 26, 2011, Pages 3574-3579

  Marchetti, Antonio ^a   Felicioni, Lara ^a   Malatesta, Sara ^a   Sciarrotta, Maria Grazia ^a   Guetti, Luigi ^a   Chella, Antonio ^b   Viola, Patrizia ^a   Pullara, Carmela ^a   Mucilli, Felice ^a   Buttitta, Fiamma ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CANCER GROWTH; CAUCASIAN; CLINICAL FEATURE; COHORT ANALYSIS; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; HETEROZYGOTE; HIGH RESOLUTION MELTING ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SEQUENCE ANALYSIS; SEX DIFFERENCE; SMOKING;

CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, ERBB-1; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053014471     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.9638     Document Type: Article

References (36)

1. Sun S, Schiller JH, Spinola M, et al: New molecularly targeted therapies for lung cancer. J Clin Invest 117:2740-2750, 2007 (Pubitemid 47529602)
2. Rosell R, Moran T, Queralt C, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967, 2007
3. Horn L, Pao W: EML4-ALK: Honing in on a new target in non-small-cell lung cancer. J Clin Oncol 27:4232-4235, 2009
4. Choi YL, Soda M, Yamashita Y, et al: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363:1734-1739, 2010
5. Pao W, Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol 12:175-180, 2011
6. Dacic S, Shuai Y, Yousem S, et al: Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 23:159-168, 2010
7. Marchetti A, Felicioni L, Pelosi G, et al: Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat 29:609-616, 2008 (Pubitemid 351614584)
8. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346, 2005 (Pubitemid 40425952)
9. Marchetti A, Martella C, Felicioni L, et al: EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857-865, 2005 (Pubitemid 46224186)
10. Shigematsu H, Takahashi T, Nomura M, et al: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65:1642-1646, 2005 (Pubitemid 40478587)
11. Buttitta F, Barassi F, Fresu G, et al: Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 119:2586-2591, 2006 (Pubitemid 44691311)
12. Marchetti A, Buttitta F, Pellegrini S, et al: Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol 179:254-259, 1996 (Pubitemid 26266402)
13. Shigematsu H, Gazdar AF: Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118:257-262, 2006 (Pubitemid 41779062)
14. Stahel RA: Adenocarcinoma, a molecular perspective. Ann Oncol 18:ix147-ix149, 2007 (suppl 9)
15. Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244-285, 2011
16. Garnett MJ, Marais R: Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313-319, 2004 (Pubitemid 39361432)
17. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002 (Pubitemid 34716871)
18. Curtin JA, Fridlyand J, Kageshita T, et al: Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147, 2005 (Pubitemid 41653105)
19. Kimura ET, Nikiforova MN, Zhu Z, et al: High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457, 2003 (Pubitemid 36373628)
20. Samowitz WS, Sweeney C, Herrick J, et al: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65:6063-6069, 2005
21. Singer G, Oldt R 3rd, Cohen Y, et al: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484-486, 2003 (Pubitemid 36432423)
22. Brose MS, Volpe P, Feldman M, et al: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997-7000, 2002 (Pubitemid 35424092)
23. Naoki K, Chen TH, Richards WG, et al: Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 62:7001-7003, 2002 (Pubitemid 35424093)
24. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
25. Sobin LH, Witteking CH (eds): TNM Classification of Malignant Tumours (ed 6). New York, NY, John Wiley & Sons, 2002
26. Marchetti A, Milella M, Felicioni L, et al: Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: An important role for mutations in minor clones. Neoplasia 11:1084-1092, 2009
27. Pratilas CA, Hanrahan AJ, Halilovic E, et al: Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 68:9375-9383, 2008
28. Sasaki H, Kawano O, Endo K, et al: Uncommon V599E BRAF mutations in Japanese patients with lung cancer. J Surg Res 133:203-206, 2006
29. Yousem SA, Nikiforova M, Nikiforov Y: The histopathology of BRAF-V600E-mutated lung adenocarcinoma. Am J Surg Pathol 32:1317-1321, 2008
30. Yamamoto H, Toyooka S, Mitsudomi T: Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 63:315-321, 2009
31. Raso MG, Behrens C, Herynk MH, et al: Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 15:5359-5368, 2009
32. Nose N, Uramoto H, Iwata T, et al: Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung. Lung Cancer 71:350-355, 2011
33. Roth AD, Tejpar S, Delorenzi M, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28:466-474, 2010
34. Paik PK, Arcila ME, Fara M, et al: Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29:2046-2051, 2011
35. Yokota T, Ura T, Shibata N, et al: BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104:856-862, 2011
36. Richman SD, Seymour MT, Chambers P, et al: KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: Results from the MRC FOCUS trial. J Clin Oncol 27:5931-5937, 2009